Lomond Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Public

Lomond Therapeutics General Information

Description

Developer of a biopharmaceutical platform designed to target escape mutations in hematological cancers. The company offers a proprietary hybrid AI platform, leveraging chem-bio expertise and proprietary data to identify molecular mechanisms of pathology, enabling biotech companies to develop therapies, and maximizing clinical benefits for patients with hematologic malignancies.

Contact Information

Website
www.lomondther.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 8 The Green
  • Suite 8490
  • Dover, DE 19901
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Artificial Intelligence & Machine Learning, Life Sciences, Oncology
Corporate Office
  • 8 The Green
  • Suite 8490
  • Dover, DE 19901
  • United States

Lomond Therapeutics Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lomond Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lomond Therapeutics‘s full profile, request access.

Request a free trial

Lomond Therapeutics Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

Lomond Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026080917-A1 Polymorphs and solid forms of a tetrahydroisoquinolinpyrazoloquinolin compound, and pharmaceutical compositions thereof Pending 11-Oct-2024
WO-2026080918-A1 Synthesis of a tetrahydroisoquinolin-pyrazoloquinolin compound and pharmaceutically acceptable salts thereof Pending 11-Oct-2024
AU-2022364646-A1 Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof Active 15-Oct-2021
AU-2022364646-B2 Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof Active 15-Oct-2021
CA-3233233-A1 Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof Pending 15-Oct-2021 C07D471/04
To view Lomond Therapeutics’s complete patent history, request access »

Lomond Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lomond Therapeutics‘s full profile, request access.

Request a free trial

Lomond Therapeutics FAQs

  • When was Lomond Therapeutics founded?

    Lomond Therapeutics was founded in 2020.

  • Where is Lomond Therapeutics headquartered?

    Lomond Therapeutics is headquartered in Dover, DE.

  • What industry is Lomond Therapeutics in?

    Lomond Therapeutics’s primary industry is Drug Discovery.

  • Is Lomond Therapeutics a private or public company?

    Lomond Therapeutics is a Public company.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process